

IDT Biologika and Takeda support production of the Johnson & Johnson single-shot COVID-19 vaccine

IDT Biologika is now using capacities at its Dessau site previously reserved for Takeda Pharmaceutical Company's dengue vaccine candidate to fill and package the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. IDT and Takeda announced an agreement to this end today. The vaccine is manufactured in Dessau for worldwide distribution.

After three months, this capacity will resume production of the TAK-003 dengue vaccine, which is crucial to its planned launch. Regulatory approval of this vaccine is pending. „I am grateful to our long-standing customer Takeda for its flexibility, which enables us to provide the world with much-needed COVID-19 vaccines,“ says Jürgen Betzing, CEO of IDT Biologika. „In recent months, it has become clear that the challenges of the pandemic can only be solved through cooperation and commitment.“

Betzing continues „This short-term agreement between three pharmaceutical companies demonstrates the willingness and ability of our industry to bring in creative ideas to solve this crisis. With our production for Janssen and AstraZeneca as well as the development of our own COVID-19 vaccine together with the German Center for Vaccine Research, our company can make an important contribution to the fight against COVID-19.“ Rajeev Venkayya, President of Takeda's Global Vaccine Division, says: “We are pleased to work with IDT to support Janssen's efforts to make its COVID-19 vaccine available and accessible to as much of the world as possible. We also recognize the massive unmet need for a dengue vaccine and will work closely with IDT to mitigate the impact on the supply of TAK-003.“

Source: idt-biologika.com

Add page

15.03.2021



THIS COULD ALSO BE OF INTEREST FOR YOU:

A Mood of Optimism in the Chemical Industry

08/04/21

The development of "new mobility" has begun to accelerate and Saxony-Anhalt is already in the fast lane, as Max Fuhr, the commercial manager of the Bitterfeld-Wolfen Chemical Park, explains: "There is a mood of optimism here, because you can't have batteries without chemicals."

MECOTEC Group from Germany delivers High-Tech Container MCF-8 for the transport and safe deep freeze cold storage at -20°C (-4°F) to -80°C (-112°F) for Covid-19 Vaccines to the Philippines

25/03/21

Presentation of the first mobile hybrid container MCF-8 in the presence of the Minister for Economics, Science and Digitization of the State of Saxony-Anhalt, Prof. Dr. Armin Willingmann, and the Deputy Ambassador Chief of Mission Ms. Lilibeth V. Pono of the Philippines in Germany

Researchers develop new combined process for 3D printing

Our website uses cookies to provide our services to you. Third party cookies are also used. By giving your approval, you agree that we may use cookies. You can change the cookie settings at any time.

Chemists at Martin Luther University Halle-Wittenberg (MLU) have developed a way to integrate liquids directly into materials during the 3D printing process. This allows, for example, active medical agents to be incorporated into pharmaceutical products or luminous liquids to be integrated into materials, which allow monitoring of damage. The study was published in "Advanced Materials Technologies".

Confirm

Settings Cookies & Privacy

